Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

• Status: Completed
• Trial end date: 2012-01-30
• Target enrollment: 0
• Participant gender: All

Summary

Patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. All patients will receive pregabalin, and half of patients will receive placebo at some point during the study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Patients must have painful diabetic peripheral neuropathy and be receiving treatment for this condition.

Exclusion Criteria:

• Patients with other pain conditions cannot participate.